Form 4: Teva Pharmaceutical Industries CEO Richard D. Francis Reports Acquisition of Restricted Share Units

Richard D. Francis, President and CEO of Teva Pharmaceutical Industries, reports the acquisition of 169,811 restricted share units on March 5, 2025.

Summary

• Richard D. Francis, the President and CEO of Teva Pharmaceutical Industries, filed a Form 4 on March 7, 2025.
• The report details the acquisition of 169,811 restricted share units on March 5, 2025.
• These restricted share units represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement.
• The restricted share units vest in installments: 42,452 on each of March 5, 2026, March 5, 2027, and March 5, 2028, and 42,455 on March 5, 2029.
• Following the transaction, Francis directly owns 169,811 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The vesting schedule promotes long-term alignment with shareholder interests.

Positives

• The acquisition of restricted share units by the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The vesting schedule of the restricted share units suggests a long-term commitment from the CEO to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates compensation and alignment of the CEO's interests with shareholders.

Stakeholder Impact

• The acquisition of restricted share units by the CEO can positively influence shareholder confidence.
• The vesting schedule incentivizes the CEO to focus on long-term value creation.

Key Dates